Drugs / ALTEMINOSTAT
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03150316 | May 2017 → Jun 2020 | plasma cell myeloma | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03051841 | Jan 2017 → Apr 2021 | plasma cell myeloma | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT01580371 | May 2012 → Mar 2016 | plasma cell myeloma | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTEMINOSTAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314954 ↗ |
| Known as | CKD-581 | “CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles” NCT03150316 ↗ |
| Modality | Small molecule | — CHEMBL5314954 ↗ |
| Route | Intravenous | “Intravenously on Days 1, 8 of each 21-day treatment cycle.” NCT03051841 ↗ |